THALES
23.5.2022 17:17:09 CEST | Business Wire | Press release
Thales announces the new Cinterion® MV32 modem card that makes it quicker and easier for manufacturers to build and maintain resilient, high-performance 5G devices that will transform everyday life in the years ahead. Harnessing the full potential of 5G Mobile Broadband connectivity, the new modem card is designed to be at the heart of a wide array of demanding IoT (Internet of Things) use cases, such as securely connecting enterprises, remote patient care and intelligent monitoring of renewable energy generation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220522005024/en/
Effortlessly connecting 5G networks and next-gen IoT devices
The 5G roll-out will not only bring unprecedented mobile broadband speed to billions of people worldwide. It also offers an extraordinary leap in the sheer number of devices that cellular networks can support. Connectivity will be enabled for billions more machines. As a result, 5G is laying the foundations for vast new fleets of permanently connected IoT devices that enable a more sustainable and trustworthy future for us all.
Many of these new IoT devices will be highly compact. Thales’ space-saving 5G modem card therefore represents the ideal partner for the tiny embedded SIMs (eSIMs) that are another key building block for effortless connectivity. Next-generation IoT applications will demand the always-on, ultra-high speed connectivity and exceptional reliability that characterises the new Cinterion MV32 modem card:
- Extensively leverages Thales’ broad expertise in providing successful 5G IoT solutions that manage connectivity plans in the field, enabling seamless, go-anywhere 5G.
- Reliably delivers superior 5G cellular performance, thanks to industry’s most advanced and optimized radio frequency design, to enable the ultra-high speed and low latency.1
Protecting against a new wave of cyber-threats
For all its benefits, the distributed, virtualized, software-based design of many 5G networks also brings with it new vulnerabilities to cyber-attack. In response, the Cinterion MV32 5G modem card embodies Thales’ unrivalled expertise and experience in bringing robust security and protection to the 5G domain:
- Leverages Thales’ security-by-design philosophy and core expertise in robust cyber-protection – enabling dynamic protection of devices in the field and over the entire lifecycle through secure remote updates.
- Stringently and continuously penetration-tested by independent security experts.
“We were able to be a first-mover in 5G branch networking devices, in part because Thales provided a great globally-certified solution with support to a wide variety of frequency bands. They also provided responsive support to our engineers and have been a reliable supplier even when everything else is in shortage. We look forward to deploying Thales’ next-gen 5G SA MV32 into our devices in the coming year.” Keith Chau, general manager, Peplink
“For our customers, the latest generation MV32 5G modem card represents just the right product at the right time. Manufacturers worldwide must look at 5G to enable revolutionary new IoT solutions that will touch every aspect of our lives. Our new solution makes it a cinch to embed this ultra-fast connectivity. There is no trade-off between speed, latency, reliability and cyber-protection: the compact MV32 delivers them all.” Thierry Uguen, Director Product Management IoT at Thales
1 Further technical annotations :
- The new Cinterion 5G data card leverages the industry-standard M.2 form factor for easy plug-and-play as well as the latest 3GPP Release 16 enhanced Mobile Broadband (eMBB) standard for peak performance.
- It consistently supports the highest levels of data throughput without overheating as a result of its sophisticated thermal design.
- Its radio frequency design also reduces complexity and increases reliability allowing the device to tap into the highest performance grade on the field, by leveraging the latest network deployments.
To learn more, join one of our virtual launch events on May 24 at 9:00 AM or 5:00 PM.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.
PLEASE VISIT
Thales Group
Digital Identity & Security
and Thales MV32 modem card
@Thalesgroup
View source version on businesswire.com: https://www.businesswire.com/news/home/20220522005024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
